



bewellconnect[®] announces the registration of MyECG[®] and MyOxy[®] with the FDA

Paris, February 8th, 2016

VISIOMED GROUP (FR0011067669 – ALVMG), a company specializing in new generation medical electronics, is pleased to announce the registration with the Food and Drug Administration (FDA) of MyOxy[®], the web-enabled pulse oximeter, and MyECG[®], the web-enabled electrocardiogram, which was presented with an Innovation Award in the Biotech category at CES 2016.

Eric SEBBAN, founder and CEO of VISIOMED GROUP, declares: *"2016 is starting strong! After the success of our participation in CES in Vegas, which accelerated our discussions with certain powerful partners, these registrations by the FDA represent the completion of the last stage and lift the last restriction on large-scale marketing by allowing MyECG[®] and MyOxy[®] to be included. This is the starting line, and we're off. We can now massively deploy all of our web-enabled medical devices, our BewellConnect[®] platform, and our subscription services BewellCheck-up[®] and MyDoc[®]. We now offer the largest range of web-enabled medical devices on the market, with high quality products registered with the FDA. This is a unique advantage. The FDA's influence reaches far beyond the American market and gives us massive opportunities on a global scale."*

Most of the BewellConnect[®] line of web-enabled medical devices has now been registered

In 2015, the key products of the BewellConnect[®] line had already received the approvals required for their sale on American territory (including the FDA's 510(k)). These products include:



New generation medical technology

- **MyGluco**[®], a blood glucose reader and a line of useful accessories (test strips, sterile lancets, control solution and auto-injection pen);
- **MyTensio**[®], an armband and wrist blood pressure monitor;
- **MyThermo**[®], a thermometer using patented **ThermoFlash**^{®1} no-contact technology;
- **MyScale**[®] Initial, a scale;
- **MyScale**[®] Analyser, a diagnostic scale;
- **MyScale**[®] XL 200kg, a special scale for high body weights;
- **MyCoach**[®], an activity and sleep tracker.

VISIOMED GROUP and its subsidiary BewellConnect Corp. USA were also registered by the FDA in late 2015, which opens up the possibility for direct sale on American territory.

Currently, while **MyTens**[®] has already received a CE mark for its sale in Europe, its registration by the FDA remains pending. The Group expects this to be achieved in the second half of 2016.

Participation in the BIO CEO & Investor Conference in New York

This recognition and judge of quality is excellent news for our deployment, arriving just as VISIOMED GROUP is preparing to meet with American investors as part of the 18th BIO CEO & Investor Conference which will take place in New York on February 8th and 9th.

The BIO CEO & Investor Conference is one of the most important investor relations events for established and emerging companies in the biotechnology and eHealth sector.

About VISIOMED GROUP

Founded in 2007 by Eric Sebban, VISIOMED GROUP specializes in new generation medical electronics. The laboratory develops and markets innovative health products in the booming field of medical and wellness self diagnosis devices. VISIOMED is notably the inventor of **ThermoFlash**[®], the first-ever contactless infrared medical thermometer.

VISIOMED combines innovation, technology and design to provide non-drug solutions for prevention and treatment focused on simplicity, comfort and the wellbeing of users.

In 2014, VISIOMED GROUP announced the launch of its range of BewellConnect[®] connected health products, thus becoming the first medical electronics laboratory to penetrate the very-high-potential IoT market (Internet-of-Things).

Based in Paris, VISIOMED GROUP is backed by a team of 105 staff including sales teams dedicated to marketing to pharmacies (OTC), to health professionals (hospitals, clinics, retirement homes) and, since late 2010, to large retailers. Group sales in 2014 were more than €13 million. VISIOMED GROUP is recognized as an "Innovative Enterprise" by Bpifrance.

VISIOMED GROUP won national 2nd place in the 2014 Deloitte In Extensio Technology Fast 50 rankings, and European 2nd place in the Health/Biotech/Pharma sector Deloitte Technology Fast 500 rankings.

For more information go to www.visiomed-lab.com.

¹ The **ThermoFlash**[®] no-contact thermometer is also authorized for sale on American territory.



New generation medical technology

CONTACTS

VISIONED GROUP

Eric Sebban

bourse@visiomed-lab.com

Chairman & CEO

+33 (0)1 40 67 06 50

ALVMG
LISTED
ALTERNEXT

ACTUS finance & communication

Jérôme Fabreguettes-Leib

visiomed@actus.fr

Investor Relations

+33 (0)1 53 67 36 78

Alexandra Prisa

aprisa@actus.fr

Financial Press Relations

+33 (0)1 53 67 36 90



TRENT & COMPANY INC.

Pamela Wadler

pam@trentandcompany.com

Press Relations

+1 212 966-0024



New generation medical technology